Quarterly Result15 May 2026, 02:46 pm
Alembic Pharma: FY26 Revenue from Operations at ₹6,651.38 Cr
AI Summary
Alembic Pharmaceuticals Ltd's board approved the standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026. The company's revenue from operations for FY26 stood at ₹6,651.38 crore. The board also recommended a dividend. The meeting commenced at 12:00 noon and concluded at 2:35 p.m. Statutory Auditors, Mis. KKC & Associates LLP, issued an audit report with an unmodified opinion on the financial results.
Key Highlights
- Alembic Pharma's board approved audited financial results for FY26.
- FY26 revenue from operations reached ₹6,651.38 crore.
- Standalone audited results show revenue from operations at ₹1,718.74 Cr for the quarter ended March 31, 2026.
- Auditors issued an unmodified opinion on the standalone and consolidated results.
- The board recommended a dividend.